| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | DEXCOM INC | 55,000 | 4,363,000 | 0.77% | ||
| 52 | ABBVIE INC | 70,000 | 4,334,000 | 0.77% | ||
| 53 | COOPER COS INC | 25,000 | 4,289,000 | 0.76% | ||
| 54 | XENCOR INC COM | 225,000 | 4,273,000 | 0.76% | ||
| 55 | VALEANT PHARMACEUTICALS INTL | 210,000 | 4,229,000 | 0.75% | ||
| 56 | NEVRO CORP COM | 54,300 | 4,005,000 | 0.71% | ||
| 57 | MACROGENICS INC | 140,000 | 3,779,000 | 0.67% | ||
| 58 | RADIUS HEALTH INCORPORATED COM NEW | 100,000 | 3,675,000 | 0.65% | ||
| 59 | LivaNova PLC | 70,000 | 3,516,000 | 0.62% | ||
| 60 | KITE PHARMA INCORPORATED | 70,000 | 3,500,000 | 0.62% | ||
| 61 | ABBOTT LABS | 84,100 | 3,306,000 | 0.59% | ||
| 62 | NXSTAGE MED INC COM | 145,300 | 3,150,000 | 0.56% | ||
| 63 | REVANCE THERAPEUTICS INC COM | 220,000 | 2,992,000 | 0.53% | ||
| 64 | KERYX BIOPHARMACEUTICALS INCORPORATED | 450,111 | 2,980,000 | 0.53% | ||
| 65 | CEMPRA INC | 171,000 | 2,820,000 | 0.50% | ||
| 66 | BECTON DICKINSON & CO | 15,000 | 2,544,000 | 0.45% | ||
| 67 | INSULET CORPORATION | 82,000 | 2,480,000 | 0.44% | ||
| 68 | PORTOLA PHARMACEUTICALS INC | 105,000 | 2,478,000 | 0.44% | ||
| 69 | NEURODERM LTD | 144,546 | 2,349,000 | 0.42% | ||
| 70 | COHERUS BIOSCIENCES INC COM | 131,357 | 2,219,000 | 0.39% | ||
| 71 | DYNAVAX TECHNOLOGIES CORP | 150,000 | 2,187,000 | 0.39% | ||
| 72 | CHIMERIX INC | 550,000 | 2,162,000 | 0.38% | ||
| 73 | HALOZYME THERAPEUTICS INC | 250,000 | 2,158,000 | 0.38% | ||
| 74 | COMMUNITY HEALTH SYS INC NEW | 175,000 | 2,109,000 | 0.37% | ||
| 75 | ACHILLION PHARMACEUTICALS IN | 266,000 | 2,075,000 | 0.37% | ||
| 76 | ADAMAS PHARMACEUTICALS INC | 130,000 | 1,968,000 | 0.35% | ||
| 77 | RIGEL PHARMACEUTICAL INC | 850,000 | 1,896,000 | 0.34% | ||
| 78 | FIBROGEN INC | 114,000 | 1,871,000 | 0.33% | ||
| 79 | NEUROCRINE BIOSCIE COM USD0.001 | 40,000 | 1,818,000 | 0.32% | ||
| 80 | PERRIGO CO PLC | 20,000 | 1,813,000 | 0.32% | ||
| 81 | ACADIA PHARMACEUTICALS INC COM | 50,000 | 1,623,000 | 0.29% | ||
| 82 | TANDEM DIABETES CARE INC COM | 209,000 | 1,576,000 | 0.28% | ||
| 83 | Esperion Therapeutics Inc | 140,000 | 1,383,000 | 0.25% | ||
| 84 | ARRAY BIOPHARMA INC | 370,000 | 1,317,000 | 0.23% | ||
| 85 | TETRAPHASE PHARMACEUTICALS INC COM | 300,000 | 1,290,000 | 0.23% | ||
| 86 | Catabasis Pharmaceuticals Inc | 345,100 | 1,277,000 | 0.23% | ||
| 87 | REGULUS THERAPEUTICS INC COM | 350,000 | 1,012,000 | 0.18% | ||
| 88 | ANTHERA PHARMACEUTICALS I | 300,000 | 927,000 | 0.16% | ||
| 89 | QUORUM HEALTH CORP | 56,250 | 602,000 | 0.11% | ||
| 90 | OREXIGEN THERAPEUTICS INC COM | 1,200,000 | 516,000 | 0.09% | ||
| 91 | ULTRAGENYX PHARMACEUTICAL INC COM | 10,000 | 489,000 | 0.09% | ||
| 92 | ADVERUM BIOTECHNOLOGIES INC | 154,006 | 487,000 | 0.09% | ||
| 93 | CONCERT PHARMACEUTICALS INCORPORATED | 30,099 | 338,000 | 0.06% | ||
| 94 | MIRATI THERAPEUTICS INC COM | 50,000 | 273,000 | 0.05% | ||
| 95 | OCULAR THERAPEUTIX INC | 40,000 | 198,000 | 0.04% | ||
| 96 | GLAUKOS CORP | 5,100 | 149,000 | 0.03% | ||
| 97 | THRESHOLD PHARMACEUTICAL INC | 201,537 | 128,000 | 0.02% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001415889-16-006640, filed 2016.08.01).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
